Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects
Conditions:   Bioavailability;   B-cell Lymphoid Cancer
Interventions:   Drug: Treatment A- Part 1;   Drug: Treatment B- Part 1;   Drug: Treatment C – Part 1;   Drug: Treatment D- Part 1;   Drug: Treatment A-Part 2;   Drug: Treatment B – Part 2;   Drug: Treatment C – Part 2;   Drug: Treatment D – Part 2
Sponsors:   AstraZeneca;   Acerta Pharma, LLC
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 28, 2020 / by / in
Comments